A COVID-19 vaccine developed by Massachusetts-based Moderna is ready for more tests after showing a promising immune system response in early-stage trials.
The National Institute of Health said that the vaccine “was generally well tolerated and prompted neutralizing antibody activity in healthy adults.”
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told The Associated Press that “this is good news.”
STAT News reported that some experts are still “withholding judgment” on the early results. Moderna will start a Phase 3 study with 30,000 patients on July 27.
Moderna’s coronavirus vaccine trial got its start at Seattle’s Kaiser Permanente Washington Health Research Institute.
The three farthest-along COVID-19 vaccines are being tested by Moderna, Johnson & Johnson, and a team including AstraZeneca and the University of Oxford. Other prospects are moving ahead as well.
